Bal Pharma cash flow

Latest FY26

Cash from operations: ₹30.8cr+48.7% on FY25
Capital spending: ₹18.6crNo figure a year before
Free cash flow: ₹12.3cr−40.8% on FY25
Cash from financing: −₹9.6cr₹0.3 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	11.1	0.0	−15.0	−7.9
	—	0.0	−15.2	0.7	−0.9
	—	16.8	−0.7	−0.5	−0.1
	—	−0.8	3.0	11.0	1.8
	—	0.0	−2.5	−0.3	4.1
	—	0.0	−2.1	−8.6	−6.9
	—	0.0	0.8	0.0	−14.6
	—	0.6	4.3	−2.0	0.3
	—	0.0	0.0	0.7	0.0
	—	0.4	0.0	−1.6	−0.8
	—	0.0	0.0	5.8	0.0
	—	−1.5	0.0	10.4	−0.0
	—	−13.3	0.0	−0.1	−0.0
	—	−1.9	−0.1	0.0	0.0
	—	0.0	0.2	−1.0	0.8
	—	−0.4	9.6	10.1	9.1
	—	0.0	0.0	0.4	0.0
	—	−13.7	16.8	15.3	12.2
	—	0.1	−1.2	−1.0	−1.0
	—	0.0	0.0	0.2	0.2
	—	7.3	−0.0	−1.2	0.0
	—	0.0	0.0	0.0	0.2
	—	15.3	−0.6	−0.6	9.2
	—	4.3	−3.5	1.3	5.4
	—	0.4	−0.0	0.4	−23.6
	—	−0.0	0.0	10.2	−31.9
	—	−0.4	6.8	0.0	−1.3
	—	0.6	0.0	1.0	26.9
Cash from operating activities
	6.9	5.9	5.1	9.0	4.7
	—	24.9	15.6	35.2	−18.7
	—	30.8	20.7	44.2	−14.0
	—	0.0	0.0	271	23.7
	—	0.0	0.0	−16.3	0.0
	—	0.0	0.0	−0.7	11.7
	—	0.0	0.0	1.5	−1.6
	—	30.8	20.7	329	23.0
Cash from investing activities
	—	17.1	0.0	0.0	0.0
	—	1.4	0.0	0.0	0.0
	—	0.1	−4.9	0.0	0.0
	—	0.0	15.7	0.0	0.0
	—	0.0	0.8	0.0	0.0
	—	0.0	0.0	0.0	−13.4
	—	0.0	0.0	0.0	0.5
	—	0.0	0.0	0.0	1.1
	—	0.0	0.0	0.0	0.4
	—	0.0	0.0	0.0	−0.9
	—	0.0	−18.8	0.0	4.4
	—	0.0	0.7	0.0	0.0
	—	0.0	3.1	0.0	0.0
	—	0.0	−0.7	0.0	0.0
	—	0.0	−16.8	0.0	0.0
	—	0.0	−2.4	0.0	0.0
	—	0.0	1.9	0.0	0.0
	—	0.0	4.1	0.0	0.0
	—	0.8	0.0	0.0	0.0
	—	−3.0	0.0	0.0	0.0
	—	−20.7	−18.1	0.0	18.4
Cash from financing activities
	—	0.0	0.0	10.4	0.0
	—	0.0	0.0	1.2	0.0
	—	0.0	0.0	−1.6	0.0
	—	0.0	0.0	5.8	0.0
	—	0.0	0.7	0.0	0.0
	—	21.8	0.9	−0.7	0.0
	—	12.7	0.0	−16.3	0.0
	—	16.8	0.0	0.0	0.0
	—	1.9	0.0	0.0	0.0
	—	−9.6	0.3	34.6	0.0
	—	0.5	2.9	364	41.5
	—	0.5	2.9	364	41.5
	—	—	—	364	41.5
Reference items
	33.8	31.9	29.6	31.5	25.1
	10.1%	10.2%	9.8%	9.3%	8.3%
	12.3	12.3	20.7	329	23.0
	—	4.6	—	338	—
	₹7.71	₹7.71	₹13.03	₹206.77	₹14.46
	11.17×	—	—	—	—
	—	4.88×	2.88×	44.21×	8.79×
	—	0.0	0.0	1.5	−1.6
	—	16.8	—	16.3	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BALPHARMA₹86.17

Bal Pharma Limited

· Pharma & Health

₹ CrorePeersALPA KREBSBIO NATCAPSUQ VINEETLAB NECLIFE AAREYDRUGS BIOFILCHEM MANGALAMMcap ₹137 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	-7.9	-15.0	0.0	11.1	—
+ Impairment Loss / (Reversal)	-0.9	0.7	-15.2	0.0	—
+ Finance Costs	-0.1	-0.5	-0.7	16.8	—
+ Interest Income	1.8	11.0	3.0	-0.8	—
+ Dividend Income	4.1	-0.3	-2.5	0.0	—
+ Fair Value (Gains) / Losses	-6.9	-8.6	-2.1	0.0	—
+ Share-based Payments	-14.6	0.0	0.8	0.0	—
+ Unrealised FX (Gain) / Loss	0.3	-2.0	4.3	0.6	—
+ Undistributed Profits of Associates	0.0	0.7	0.0	0.0	—
+ Other Non-cash Items	-0.8	-1.6	0.0	0.4	—
+ Other — Cash Effects are Investing / Financing	0.0	5.8	0.0	0.0	—
+ Other Reconciling Items	-0.0	10.4	0.0	-1.5	—
Changes in Working Capital
+ Inventories	-0.0	-0.1	0.0	-13.3	—
+ Trade Receivables — Current	0.0	0.0	-0.1	-1.9	—
+ Trade Receivables — Non-current	0.8	-1.0	0.2	0.0	—
+ Other Financial Assets — Current	9.1	10.1	9.6	-0.4	—
+ Other Financial Assets — Non-current	0.0	0.4	0.0	0.0	—
+ Other Current Assets	12.2	15.3	16.8	-13.7	—
+ Other Non-current Assets	-1.0	-1.0	-1.2	0.1	—
+ Other Bank Balances	0.2	0.2	0.0	0.0	—
+ Trade Payables — Current	0.0	-1.2	-0.0	7.3	—
+ Trade Payables — Non-current	0.2	0.0	0.0	0.0	—
+ Other Financial Liabilities — Current	9.2	-0.6	-0.6	15.3	—
+ Other Financial Liabilities — Non-current	5.4	1.3	-3.5	4.3	—
+ Other Current Liabilities	-23.6	0.4	-0.0	0.4	—
+ Other Non-current Liabilities	-31.9	10.2	0.0	-0.0	—
+ Provisions — Current	-1.3	0.0	6.8	-0.4	—
+ Provisions — Non-current	26.9	1.0	0.0	0.6	—
Cash from Operating Activities
Profit Before Tax (per I/S)	4.7	9.0	5.1	5.9	6.9
+ Total Adjustments (incl. Working Capital)	-18.7	35.2	15.6	24.9	—
Cash from Operations (pre-tax)	-14.0	44.2	20.7	30.8	—
+ Interest Received — Operating	23.7	270.9	0.0	0.0	—
+ Interest Paid — Operating	0.0	-16.3	0.0	0.0	—
+ Dividends Received — Operating	11.7	-0.7	0.0	0.0	—
+ Income Taxes Paid	-1.6	1.5	0.0	0.0	—
Cash from Operating Activities	23.0	329.2	20.7	30.8	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	0.0	0.0	0.0	17.1	—
+ Acq of Intangible Assets	0.0	0.0	0.0	1.4	—
+ Disp of Fixed Assets	0.0	0.0	-4.9	0.1	—
+ Acq of Biological Assets	0.0	0.0	15.7	0.0	—
+ Acq of Other Long-term Assets	0.0	0.0	0.8	0.0	—
+ Purchase of Investments (Equity / Debt)	-13.4	0.0	0.0	0.0	—
+ Sale of Investments (Equity / Debt)	0.5	0.0	0.0	0.0	—
+ Acq of Interests in Joint Ventures	1.1	0.0	0.0	0.0	—
+ Disp of Interests in Joint Ventures	0.4	0.0	0.0	0.0	—
+ Acq of Subsidiaries / Businesses (net)	-0.9	0.0	0.0	0.0	—
+ Disp of Subsidiaries / Businesses (net)	4.4	0.0	-18.8	0.0	—
+ Investment in Partnership Firms / LLPs	0.0	0.0	0.7	0.0	—
+ Share of Profits — Partnership Firms / LLPs	0.0	0.0	3.1	0.0	—
+ Loans & Advances Repaid	0.0	0.0	-0.7	0.0	—
+ Payments on Futures / Forwards / Options / Swaps	0.0	0.0	-16.8	0.0	—
+ Receipts on Futures / Forwards / Options / Swaps	0.0	0.0	-2.4	0.0	—
+ Government Grants Received	0.0	0.0	1.9	0.0	—
+ Dividends Received — Investing	0.0	0.0	4.1	0.0	—
+ Interest Received — Investing	0.0	0.0	0.0	0.8	—
+ Other Inflows / (Outflows) — Investing	0.0	0.0	0.0	-3.0	—
Cash from Investing Activities	18.4	0.0	-18.1	-20.7	—
Cash from Financing Activities
+ Proceeds from Other Equity Instruments	0.0	10.4	0.0	0.0	—
+ Proceeds from Exercise of Stock Options	0.0	1.2	0.0	0.0	—
+ Buyback / Redemption of Own Shares	0.0	-1.6	0.0	0.0	—
+ Proceeds — Change in Ownership of Subsidiaries	0.0	5.8	0.0	0.0	—
+ Payments — Change in Ownership of Subsidiaries	0.0	0.0	0.7	0.0	—
+ Proceeds from Borrowings	0.0	-0.7	0.9	21.8	—
+ Repayment of Borrowings	0.0	-16.3	0.0	12.7	—
+ Interest Paid	0.0	0.0	0.0	16.8	—
+ Dividends Paid	0.0	0.0	0.0	1.9	—
Cash from Financing Activities	0.0	34.6	0.3	-9.6	—
Net Changes in Cash (pre-FX)	41.5	363.8	2.9	0.5	—
Net Changes in Cash	41.5	363.8	2.9	0.5	—
Closing Cash	41.5	363.8	—	—	—
Reference Items
EBITDA	25.1	31.5	29.6	31.9	33.8
EBITDA Margin %	8.26	9.29	9.75	10.24	10.10
Free Cash Flow (CFO − Capex)	23.0	329.2	20.7	12.3	12.3
Free Cash Flow to Equity	—	337.8	—	4.6	—
Free Cash Flow per Basic Share	14.46	206.77	13.03	7.71	7.71
Price to Free Cash Flow	—	—	—	—	11.17
Cash Flow to Net Income	8.79	44.21	2.88	4.88	—
Cash Paid for Taxes	-1.6	1.5	0.0	0.0	—
Cash Paid for Interest	—	16.3	—	16.8	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.